FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2938884099> ?p ?o ?g. }

• W2938884099 endingPage "198" @default.
• W2938884099 startingPage "185" @default.
• W2938884099 abstract "This retrospective analysis compares the probability of target attainment (PTA) for ceftriaxone, levofloxacin and ceftaroline fosamil against Staphylococcus aureus, Streptococcus pneumoniae and Haemophilus influenzae in a representative patient population with moderate-to-severe community-acquired pneumonia (CAP).Published pharmacokinetic (PK) models for levofloxacin and ceftriaxone, and an existing model for ceftaroline, were used with standard dosage regimens for simulating individual PK data with covariates representative of patients with CAP (5000 patients/drug regimen). PTA for clinically relevant pharmacokinetic/pharmacodynamic (PK/PD) targets was calculated from steady state PK profiles for a range of minimum inhibitory concentrations (MICs). Cumulative fractions of response (CFRs) were also calculated using MIC distributions from 2012 to 2017 global surveillance data.Ceftaroline fosamil (600 mg q12 h) achieved > 90% PTA at all exposure targets for each pathogen at European Committee on Antimicrobial Susceptibility Testing (EUCAST)/Clinical and Laboratory Standards Institute (CLSI) susceptibility breakpoints, and CFRs were > 99%. Ceftriaxone, but not levofloxacin, achieved 100% PTA and > 90% CFR against S. pneumoniae. Both levofloxacin and ceftriaxone achieved high PTA and CFR against H. influenzae. Levofloxacin achieved PTAs < 90% at EUCAST/CLSI breakpoints and ceftriaxone achieved PTAs < 90% at MICs up to 2 mg/L against S. aureus; both agents produced generally low CFRs against S. aureus (except levofloxacin against methicillin-sensitive S. aureus), reflecting the lack of activity of these agents against methicillin-resistant S. aureus.Ceftaroline fosamil demonstrated higher overall PTA rates than levofloxacin and ceftriaxone, in particular against S. aureus. These results provide insight regarding the potential comparative efficacy of the described antibiotics for moderate-to-severe CAP.Pfizer." @default.
• W2938884099 created "2019-04-25" @default.
• W2938884099 creator A5003940986 @default.
• W2938884099 creator A5014348590 @default.
• W2938884099 creator A5020992600 @default.
• W2938884099 creator A5035996923 @default.
• W2938884099 creator A5045989418 @default.
• W2938884099 creator A5081984076 @default.
• W2938884099 date "2019-04-08" @default.
• W2938884099 modified "2023-10-01" @default.
• W2938884099 title "A Retrospective Analysis of Probability of Target Attainment in Community-Acquired Pneumonia: Ceftaroline Fosamil Versus Comparators" @default.
• W2938884099 cites W1526371090 @default.
• W2938884099 cites W1732153887 @default.
• W2938884099 cites W1963946856 @default.
• W2938884099 cites W1974702981 @default.
• W2938884099 cites W1994788843 @default.
• W2938884099 cites W2004627090 @default.
• W2938884099 cites W2007844772 @default.
• W2938884099 cites W2012367634 @default.
• W2938884099 cites W2016820377 @default.
• W2938884099 cites W2019799507 @default.
• W2938884099 cites W2023956656 @default.
• W2938884099 cites W2030747641 @default.
• W2938884099 cites W2034794380 @default.
• W2938884099 cites W2038873356 @default.
• W2938884099 cites W2043967124 @default.
• W2938884099 cites W2051393125 @default.
• W2938884099 cites W2055885818 @default.
• W2938884099 cites W2075960672 @default.
• W2938884099 cites W2079522835 @default.
• W2938884099 cites W2081562340 @default.
• W2938884099 cites W2098920479 @default.
• W2938884099 cites W2104273970 @default.
• W2938884099 cites W2112694597 @default.
• W2938884099 cites W2112785743 @default.
• W2938884099 cites W2115405489 @default.
• W2938884099 cites W2116089057 @default.
• W2938884099 cites W2119664237 @default.
• W2938884099 cites W2124584779 @default.
• W2938884099 cites W2127059473 @default.
• W2938884099 cites W2133440505 @default.
• W2938884099 cites W2133979383 @default.
• W2938884099 cites W2145484866 @default.
• W2938884099 cites W2149362635 @default.
• W2938884099 cites W2155982642 @default.
• W2938884099 cites W2160529501 @default.
• W2938884099 cites W2161209134 @default.
• W2938884099 cites W2162465279 @default.
• W2938884099 cites W2167943565 @default.
• W2938884099 cites W2168147536 @default.
• W2938884099 cites W2171722987 @default.
• W2938884099 cites W2320270386 @default.
• W2938884099 cites W2401513239 @default.
• W2938884099 cites W2495444602 @default.
• W2938884099 cites W2521096373 @default.
• W2938884099 cites W2530049583 @default.
• W2938884099 cites W2899045758 @default.
• W2938884099 cites W2916433178 @default.
• W2938884099 cites W4232707487 @default.
• W2938884099 doi "https://doi.org/10.1007/s40121-019-0243-4" @default.
• W2938884099 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6522587" @default.
• W2938884099 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30963520" @default.
• W2938884099 hasPublicationYear "2019" @default.
• W2938884099 type Work @default.
• W2938884099 sameAs 2938884099 @default.
• W2938884099 citedByCount "13" @default.
• W2938884099 countsByYear W29388840992019 @default.
• W2938884099 countsByYear W29388840992020 @default.
• W2938884099 countsByYear W29388840992021 @default.
• W2938884099 countsByYear W29388840992022 @default.
• W2938884099 countsByYear W29388840992023 @default.
• W2938884099 crossrefType "journal-article" @default.
• W2938884099 hasAuthorship W2938884099A5003940986 @default.
• W2938884099 hasAuthorship W2938884099A5014348590 @default.
• W2938884099 hasAuthorship W2938884099A5020992600 @default.
• W2938884099 hasAuthorship W2938884099A5035996923 @default.
• W2938884099 hasAuthorship W2938884099A5045989418 @default.
• W2938884099 hasAuthorship W2938884099A5081984076 @default.
• W2938884099 hasBestOaLocation W29388840991 @default.
• W2938884099 hasConcept C126322002 @default.
• W2938884099 hasConcept C2776102371 @default.
• W2938884099 hasConcept C2776520383 @default.
• W2938884099 hasConcept C2776925733 @default.
• W2938884099 hasConcept C2777914695 @default.
• W2938884099 hasConcept C2781253189 @default.
• W2938884099 hasConcept C2781276175 @default.
• W2938884099 hasConcept C2781413609 @default.
• W2938884099 hasConcept C2908647359 @default.
• W2938884099 hasConcept C501593827 @default.
• W2938884099 hasConcept C71924100 @default.
• W2938884099 hasConcept C86803240 @default.
• W2938884099 hasConcept C89423630 @default.
• W2938884099 hasConcept C98274493 @default.
• W2938884099 hasConcept C99454951 @default.
• W2938884099 hasConceptScore W2938884099C126322002 @default.
• W2938884099 hasConceptScore W2938884099C2776102371 @default.
• W2938884099 hasConceptScore W2938884099C2776520383 @default.
• W2938884099 hasConceptScore W2938884099C2776925733 @default.

• next